There was a decline in Hb levels in all patients (median Hb change, −1.0 g/dL); eighteen developed a newly positive direct antiglobulin tests without evidence of hemolysis and there were increased transfusion requirements among nineteen patients with relapsed/refractory AML [109]. This evidence concerns the gene GSTM1 and acute myeloid leukemia.